Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.

Vincenzo AdamoGiuseppina Rosaria Rita RicciardiDario GiuffridaGiuseppa ScandurraAntonio RussoLivio BlasiPietro SpadaroCarmelo IaconoHector J Soto ParraAntonino SavarinoFrancesco FerraúFilippo ZerilliFrancesco VerderameAlfredo ButeraCarlo SantangeloVeronica FranchinaMichele Caruso

Published in: Therapeutic advances in medical oncology (2019)

Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.

Keyphrases

metastatic breast cancer
clinical trial
stem cells
randomized controlled trial
insulin resistance
study protocol
combination therapy
adipose tissue
cell therapy